RLYB News and Press, Rallybio Corporation From 06/02/22

--Company initiates an external search for its next Chief Financial Officer-- Rallybio Corporation (Nasdaq: RLYB), a clinical-stage biotechnology company committed to identifying and accelerating the development of life-transforming therapies for patients with severe and rare di...

Rallybio Corporation (Nasdaq: RLYB), a clinical-stage biotechnology company committed to identifying and accelerating the development of life-transforming therapies for patients with severe and rare diseases, today announced its participation in the following upcoming investor conferenc...

Rallybio press release (NASDAQ:RLYB): Q1 GAAP EPS of -$0.48 misses by $0.01. As of March 31, 2022, cash, cash equivalents, and marketable securities were $161.4 million. For further details see: Rallybio GAAP EPS of -$0.48 misses by $0.01

The clinical-stage biotech Rallybio Corporation (NASDAQ:RLYB) said on Tuesday it received the worldwide exclusive rights to KY1066, a monoclonal antibody developed by Sanofi (SNY) to treat blood disorders such as beta-thalassemia (BT) and a group of myelodysplastic syndromes (MDS). With the t...

-- Initiated Phase 1b proof-of-concept study for RLYB212 for the prevention of FNAIT; initial data expected in 3Q 2022 -- -- Phase 1 study of RLYB116 ongoing; initial single dose safety, PK, and PD data expected in 2H 2022 -- -- Acquired RLYB331 from Sanofi, a pote...

--Expands pipeline focus on rare benign hematological disorders-- --Licensing agreement marks first business development transaction since IPO -- Rallybio Corporation (Nasdaq: RLYB), a clinical-stage biotechnology company committed to identifying and accelera...

-Tim Shannon, M.D. to resign from Rallybio’s Board of Directors effective at 2022 Annual Meeting of Shareholders- Rallybio Corporation (Nasdaq: RLYB), a clinical-stage biotechnology company committed to identifying and accelerating the development of life-transfor...

Halvorsen's 13F portfolio value decreased from $36.04B to $34.49B this quarter. The number of positions increased from 96 to 107. Viking Global added Twilio, Workday, and Aon plc while dropping Fidelity National Information Services and Snowflake. The top three positions are Ginkg...

Rallybio press release (NASDAQ:RLYB): Q4 GAAP EPS of -$0.42 misses by $0.01. As of December 31, 2021, cash and cash equivalents were $175.3M. For further details see: Rallybio GAAP EPS of -$0.42 misses by $0.01

-- Phase 1b proof-of-concept study for RLYB212 in development for the prevention of FNAIT on track to commence in 2Q 2022; initial data expected in 3Q 2022 -- -- First healthy volunteers dosed in Phase 1 study of RLYB116; single dose safety, PK, and PD data expected in 2H 2022...